Alivus Life Sciences share news, announcements and annual reports
NSE: ALIVUSBSE: 543322Pharmaceuticals & BiotechnologySmall Cap
Alivus Life Sciences Limited · Formerly Glenmark Life Sciences · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2021 · Issue price ₹720
Last close ₹1,397.40down ₹2.00 (0.14%)BSE ₹1,397.75
Share price at the NSE close on 29 Oct 2026. Previous close ₹1,399.40.
29 Oct: open ₹1,400.00, high ₹1,437.40, low ₹1,385.00
52-week range of traded prices to 29 Oct 2026
₹819.00Low, 22 Jan 2026₹1,493.80High, 31 Aug 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹17,156 Cr502nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 25.62
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.72
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.36%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 23.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,64,40054.0% delivered
Alivus Life Sciences analyst meets
83 filed, newest first. Page 2 of 2.
Oct 2024
25 Oct · Analysts
18 Oct · Analysts
Sep 2024
16 Sep · Analysts
3 Sep · Analysts
Aug 2024
28 Aug · Analysts
19 Aug · Analysts
8 Aug · Analysts
7 Aug · Analysts
Jul 2024
18 Jul · Analysts
Jun 2024
21 Jun · Analysts
20 Jun · Analysts
13 Jun · Analysts
12 Jun · Analysts
May 2024
31 May · Analysts
27 May · Analysts
16 May · Analysts
14 May · Analysts
Apr 2024
19 Apr · Analysts
Mar 2024
6 Mar · Analysts
Jan 2024
17 Jan · Analysts
Oct 2023
16 Oct · Analysts
Jul 2023
14 Jul · Analysts
Apr 2023
20 Apr · Analysts
Jan 2023
18 Jan · Analysts
Nov 2022
Oct 2022
Jul 2022
Apr 2022
Feb 2022
1 Feb · Analysts
Nov 2021
3 Nov · Analysts
Aug 2021
9 Aug · Analysts